-
1
-
-
77949383588
-
Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
-
Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010; 64: 651-60.
-
(2010)
Int J Clin Pract
, Issue.64
, pp. 651-660
-
-
Grossberg, G.T.1
Sadowsky, C.2
Olin, J.T.3
-
2
-
-
84938430397
-
Rivastigmine for Alzheimer's disease
-
CD001191
-
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2006; 15: CD001191.
-
(2006)
Cochrane Database Syst Rev
, vol.15
-
-
Birks, J.1
Grimley Evans, J.2
Iakovidou, V.3
Tsolaki, M.4
Holt, F.E.5
-
3
-
-
0036257075
-
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: An hypothesis
-
Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 206-14.
-
(2002)
Int J Clin Pract
, vol.56
, pp. 206-214
-
-
Bullock, R.1
-
4
-
-
10044283107
-
Rivastigmine for dementia associated with Parkinson's disease
-
Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
-
(2004)
N Engl J Med
, vol.351
, pp. 2509-2518
-
-
Emre, M.1
Aarsland, D.2
Albanese, A.3
-
5
-
-
0034676757
-
Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
-
McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
-
(2000)
Lancet
, vol.356
, pp. 2031-2036
-
-
McKeith, I.1
Del Ser, T.2
Spano, P.3
-
6
-
-
64149090366
-
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review
-
Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009; 63: 799-805.
-
(2009)
Int J Clin Pract
, vol.63
, pp. 799-805
-
-
Kurz, A.1
Farlow, M.2
Lefèvre, G.3
-
7
-
-
36248987178
-
Rotigotine transdermal patch: A review of its use in the management of Parkinson's disease
-
Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007; 21: 1039-55.
-
(2007)
CNS Drugs
, vol.21
, pp. 1039-1055
-
-
Baldwin, C.M.1
Keating, G.M.2
-
8
-
-
51749085099
-
Rotigotine transdermal patch: In restless legs syndrome
-
Baldwin CM, Keating GM. Rotigotine transdermal patch: in restless legs syndrome. CNS Drugs 2008; 22: 797-806.
-
(2008)
CNS Drugs
, vol.22
, pp. 797-806
-
-
Baldwin, C.M.1
Keating, G.M.2
-
9
-
-
2342523953
-
Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia
-
Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937-47.
-
(2004)
Drugs
, vol.64
, pp. 937-947
-
-
Davies, P.S.1
Galer, B.S.2
-
10
-
-
34249683625
-
A six-month double-blind, randomized, placebo-controlled study of transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule
-
Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
-
(2007)
Int J Geriatr Psychiatry
, vol.22
, pp. 456-467
-
-
Winblad, B.1
Cummings, J.2
Andreasen, N.3
-
11
-
-
67651071488
-
Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension
-
Grossberg G, Sadowsky C, Forstl H et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009; 23: 158-64.
-
(2009)
Alzheimer Dis Assoc Disord
, vol.23
, pp. 158-164
-
-
Grossberg, G.1
Sadowsky, C.2
Forstl, H.3
-
12
-
-
34249705681
-
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease
-
Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-91.
-
(2007)
Int J Geriatr Psychiatry
, vol.22
, pp. 485-491
-
-
Winblad, B.1
Kawata, A.K.2
Beusterien, K.M.3
-
13
-
-
66149089567
-
Transdermal rivastigmine patch in outpatient services in Austria: A naturalistic study in 103 patients with Alzheimer dementia
-
in German
-
Schmidt R, Alf C, Bancher C et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia [in German]. Neuropsychiatr 2009; 23: 58-63.
-
(2009)
Neuropsychiatr
, vol.23
, pp. 58-63
-
-
Schmidt, R.1
Alf, C.2
Bancher, C.3
-
14
-
-
0345276668
-
Strategies for continued successful treatment of Alzheimer's disease: Switching cholinesterase inhibitors
-
Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19: 707-14.
-
(2003)
Curr Med Res Opin
, vol.19
, pp. 707-714
-
-
Gauthier, S.1
Emre, M.2
Farlow, M.R.3
Bullock, R.4
Grossberg, G.T.5
Potkin, S.G.6
-
15
-
-
68149107608
-
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease
-
Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009; 24: 267-75.
-
(2009)
Am J Alzheimers Dis Other Demen
, vol.24
, pp. 267-275
-
-
Sadowsky, C.H.1
Dengiz, A.2
Olin, J.T.3
Koumaras, B.4
Meng, X.5
Brannan, S.6
-
16
-
-
72049131568
-
Hepatitis with cholestasis caused by rivastigmine transdermal patch
-
Mumoli N, Carmignani G, Luschi R, Cei M, Chiavistelli P. Hepatitis with cholestasis caused by rivastigmine transdermal patch. Am J Gastroenterol 2009; 104: 2859-60.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2859-2860
-
-
Mumoli, N.1
Carmignani, G.2
Luschi, R.3
Cei, M.4
Chiavistelli, P.5
-
17
-
-
78049470959
-
-
Larner AJ. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev Neurotherapeutics 2010; 10. in press.
-
Larner AJ. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev Neurotherapeutics 2010; 10. in press.
-
-
-
-
18
-
-
34248372938
-
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study
-
Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501-12.
-
(2007)
Lancet Neurol
, vol.6
, pp. 501-512
-
-
Feldman, H.H.1
Ferris, S.2
Winblad, B.3
-
19
-
-
70349306585
-
Cholinesterase inhibition: Is there evidence for disease-modifying effects?
-
Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 2009; 25: 2439-46.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2439-2446
-
-
Shanks, M.1
Kivipelto, M.2
Bullock, R.3
Lane, R.4
|